- Policy
- KAPO demands MFDS to swiftly approve Lutathera
- by Lee, Jeong-Hwan May 13, 2020 05:54am
- A patient group once again urged for a prompt approval review on neuroendocrine tumor treatment Lutathera (lutetium Lu 177 dotatate). The group demanded the Korean government to take action fast for the patients with neuroendocrine tumor in agony with inevitable overseas treatment and burdensome pharmaceutical expense amid COVID-19 pande
- Opinion
- [Reporter’s view] Yuhan's CEO Lee made a big decision
- by Lee, Seok-Jun May 13, 2020 05:54am
- Jung Hee Lee, Yuhan CEO, is due until March next year. This is due to the company's policy of having two consecutive terms in three years. It will end in March next year. since he started working in March 2015. Most CEOs make their performances within their tenure. This is because 'maximum performance since its founding' can be a 'decoration'
- Company
- New osteoporosis drug Evenity applies for reimbursement
- by Eo, Yun-Ho May 13, 2020 05:54am
- Evenity, a novel bone-builder that reduces bone loss, is seeking for healthcare reimbursement in Korea. According to pharmaceutical industry sources, Amgen Korea has recently submitted an application for healthcare reimbursement on Evenity (romososumab) with a dual effect of increasing bone formation and to a lesser extent reducing bone
- Policy
- Whanin, begins development of first generic for Fycompa
- by Lee, Tak-Sun May 13, 2020 05:54am
- Whanin, for the first time as a domestic pharmaceutical company, started developing generics for antiepileptic drug Fycompa by Eisai. If the generic development proceeds smoothly, it is expected that it will be aprproved next year as soon as possible. The MFDS approved the bioequivalence test plan for 'Peranel 6mg' submitted by Whanin on t
- Company
- Boryung, acquires domestic sales rights for Lilly's GemZar
- by Kim, Jin-Gu May 13, 2020 05:53am
- Boryung acquired the domestic right for the anticancer drug 'GemZar (Gemcitabine HCl)' held by Eli Lilly. Boryung announced on the 8th that it had signed a contract to transfer assets to Eli Lilly and Gemzar. Through this agreement, Boryung has all rights, including domestic rights and licenses of Gemzar. Boryung and Eli Lilly have been co
- Company
- Itaewon club-linked COVID-19 threatens the industry
- by An, Kyung-Jin May 12, 2020 06:28am
- The pharmaceutical industry is straining as the number of confirmed COVID-19 from Seoul Itaewon Club increases. Pharmaceutical companies in the Seoul Square building where COVID-19 confirmed patients visited Itaewon went into emergency telecommuting, and nearby pharmaceutical companies are also watching closely. According to the industry
- Company
- Delay in choline alfoscerate reimbursement reevaluation
- by Kim, Jin-Gu May 12, 2020 06:28am
- The sources speculate the Korean pharmaceutical industry’s hot potato, the reimbursement feasibility reevaluation on choline Alfoscerate would be postponed to the latter half of the year. On May 11, pharmaceutical industry sources reported the reimbursement reevaluation on choline alfoscerate has been pressed on since the last year’s N
- Policy
- Chong Kun Dang to enhance Eliquis generic quality
- by Lee, Tak-Sun May 12, 2020 06:27am
- Chong Kun Dang is to enhance quality of Liquisia, a generic version of coagulant medicine Eliquis. Currently leading the Eliquis generic market, Liquisia is aiming for sales expansion through the substance quality improvement. On Apr. 29, Ministry of Food and Drug Safety (MFDS) approved of bioequivalence test plan for Liquisia (apixaban)
- Company
- Teva gave Celltrion ₩200 billion in copyright deposit
- by An, Kyung-Jin May 12, 2020 06:27am
- Celltrion group surpassed the exclusive rights of the two biosimilars in North America, and it was found that it generated a technology fee of nearly &8361;200 billion. In a report submitted to the Securities and Exchange Commission (SEC) on the 7th (local time), multinational pharmaceutical company Teva revealed the history of a biosi
- Policy
- Ongentys will be reimbursed upon accepting the committee
- by Lee, Hye-Kyung May 12, 2020 06:27am
- SK Chemicals' new drug 'Ongentys (Opicapone)', which is a new treatment for Parkinson's disease, ,accepts below the evaluation amount of the Pharmaceutical Benefits Advisory Committee the reimbursed price will likely pass. The HIRA (President Seon-min Kim) released the results of the deliberation on the adequacy of the medical care benefit
